Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
The antibody was designed and developed at Abzena’s Cambridge, UK,
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
